Fulgent Genetics Inc
Ownership
Ownership Structure
Who owns Fulgent Genetics Inc (FLGT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 60.7% of the shares are freely tradable; institutional investors hold 63.5%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.31 | 2,286,669 | -17.6 | 06/30/2026 |
| Acadian Asset Management LLC | 3.70 | 1,017,913 | -17.5 | 06/30/2026 |
| Vanguard Capital Management, LLC | 2.87 | 789,498 | -10.3 | 06/30/2026 |
| Jacobs Levy Equity Management, Inc. | 2.84 | 782,116 | +119.5 | 06/30/2026 |
| JPMorgan Chase & Co | 2.75 | 756,558 | +64.3 | 06/30/2026 |
| Diametric Capital, LP | 2.54 | 697,784 | +93.3 | 06/30/2026 |
| Ameriprise Financial Inc | 2.44 | 670,084 | +18.9 | 06/30/2026 |
| Dimensional Fund Advisors, Inc. | 2.27 | 625,355 | -6.9 | 06/30/2026 |
| Geode Capital Management, LLC | 1.89 | 521,014 | -10.8 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.01 | 551,839 | +0.0 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Gao Hanlin | Chief Scientific Officer | 984,472 | 19,000,310 $ | Oct 26, 2026 | direct |
| Hsieh Ming | Chief Executive Officer | 885,952 | 17,098,874 $ | Sep 1, 2026 | direct |
| Xie Jian | President and COO | 355,563 | 6,862,366 $ | Oct 26, 2026 | direct |
| Kim Paul | CFO and Treasurer | 353,795 | 6,828,244 $ | Oct 26, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 26, 2026 | Gao Hanlin | Chief Scientific Officer | Other | 1,645 | 20.22 | 33,262 |
| Oct 26, 2026 | Xie Jian | President and COO | Other | 4,361 | 20.22 | 88,179 |
| Oct 26, 2026 | Kim Paul | CFO and Treasurer | Other | 2,748 | 20.22 | 55,565 |
| Sep 2, 2026 | Xie Jian | President and COO | Sell | 2,127 | 19.66 | 41,809 |
| Sep 2, 2026 | Gao Hanlin | Chief Scientific Officer | Sell | 1,673 | 19.66 | 32,885 |
| Sep 1, 2026 | Hsieh Ming | Chief Executive Officer | Other | 4,392 | 19.59 | 86,039 |
| Sep 1, 2026 | Kim Paul | CFO and Treasurer | Other | 2,087 | 19.59 | 40,884 |
| Aug 27, 2026 | Xie Jian | President and COO | Sell | 1,193 | 19.91 | 23,747 |
| Aug 27, 2026 | Gao Hanlin | Chief Scientific Officer | Sell | 939 | 19.91 | 18,691 |
| Aug 26, 2026 | Hsieh Ming | Chief Executive Officer | Other | 2,949 | 19.81 | 58,420 |
| Aug 26, 2026 | Kim Paul | CFO and Treasurer | Other | 1,168 | 19.81 | 23,138 |
| Jul 26, 2026 | Kim Paul | CFO and Treasurer | Other | 2,747 | 19.67 | 54,033 |
| Jul 26, 2026 | Xie Jian | President and COO | Other | 4,361 | 19.67 | 85,781 |
| Jul 26, 2026 | Gao Hanlin | Chief Scientific Officer | Other | 1,645 | 19.67 | 32,357 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.